What are some checkpoint inhibitors in clinics?

— Three FDA approved mAbs, all are anti-PD-L1 — Atezolizumab (Tecentriq): — Humanized IgG1 — Approved in March 2019. Used in combination with chemotherapy for the treatment of Non-small cell lung carcinoma (NSCLC) and explored for many cancers including prostate, colon, pancreas, gastric,… — Durvalumab (Keytruda) : human IgG1 indicated mainly for advanced melanoma — Avelumab (Bavencio) : human IgG1 indicated mainly for NSCLC